Lead Product(s) : Nelipepimut-S,Sargramostim
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SELLAS Announces Positive Antigen-Specific Immune Response Data for Nelipepimut-S (NPS) in Women
Details : Preliminary data show 11-fold increase in CD8 cytotoxic T-lymphocytes immune response in patients who received single dose of NPS compared to baseline.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 18, 2020
Lead Product(s) : Nelipepimut-S,Sargramostim
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nelipepimut-S
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Genentech | Sellas Life Sciences Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : NeuVax
Product Type : Vaccine
Upfront Cash : Inapplicable
November 21, 2014
Lead Product(s) : Nelipepimut-S
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Genentech | Sellas Life Sciences Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nelipepimut-S
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : NeuVax vaccine
Product Type : Vaccine
Upfront Cash : Inapplicable
November 24, 2011
Lead Product(s) : Nelipepimut-S
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable